Scotiabank initiated coverage of Bristol Myers (BMY) with a Sector Perform rating and $45 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Pharma firms spending billions on treatments based off old drugs, Bloomberg says
- FDA appoints Richard Pazdur as Director of CDER
- Bristol-Myers Squibb Completes €5 Billion Note Offering
- Cytokinetics price target raised to $90 from $80 at B. Riley
- Bristol Myers price target lowered to $62 from $64 at Piper Sandler